<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03754049</url>
  </required_header>
  <id_info>
    <org_study_id>TLC599A2004</org_study_id>
    <nct_id>NCT03754049</nct_id>
  </id_info>
  <brief_title>A Phase 2, Open Label, PK Study of TLC599 in Subject With Osteoarthritis of the Knee</brief_title>
  <official_title>A Phase 2, Open-label, Pharmacokinetic Study of a Single Intra-articular Administration of TLC599 in Subjects With Mild to Moderate Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Liposome Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Liposome Company</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 2, open-label, 1-period, parallel study with 9 cohorts of subjects with&#xD;
      OA of the knee enrolled to receive single-dose of TLC599 or DSP via IA injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 2, open-label, 1 period, parallel study will enroll approximately 90 subjects to&#xD;
      receive a single dose of TLC599 or DSP via IA injection, followed by a PK evaluation period&#xD;
      up to 24 weeks and an additional follow-up period of 1 to 5 weeks. Additional subjects will&#xD;
      be recruited as needed, to collect adequate SF volume for DP and DEX concentration analysis&#xD;
      at EOPK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the Curve [AUC]</measure>
    <time_frame>Baseline till 24 weeks post IP administration</time_frame>
    <description>Area under the concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: maximum concentration</measure>
    <time_frame>Baseline till 24 weeks post IP administration</time_frame>
    <description>Maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: time to peak concentration</measure>
    <time_frame>Baseline till 24 weeks post IP administration</time_frame>
    <description>Time to peak concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of AEs, including SAE and treatment-emergent AE</measure>
    <time_frame>Screening till 25 weeks post IP administration</time_frame>
    <description>Number of AEs, including SAE and treatment-emergent AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol concentration</measure>
    <time_frame>baseline till 24 weeks post IP administration</time_frame>
    <description>Cortisol concentration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>OSTEOARTHRITIS OF THE KNEE</condition>
  <arm_group>
    <arm_group_label>TLC599 12 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg DSP with 100 μmol phospholipid via IA injection;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLC599 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg DSP with 50 μmol phospholipid via IA injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSP 4mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone Sodium Phosphate (DSP): 4 mg/mL, 1 mL via IA injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TLC599</intervention_name>
    <description>TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).</description>
    <arm_group_label>TLC599 12 mg</arm_group_label>
    <arm_group_label>TLC599 6 mg</arm_group_label>
    <other_name>TLC599 Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP</intervention_name>
    <description>Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.</description>
    <arm_group_label>DSP 4mg</arm_group_label>
    <other_name>Dexamethasone Sodium Phosphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female non or moderate smokers, 45 years or older, with BMI ≤ 40.0 kg/m2.&#xD;
&#xD;
          2. Has symptoms associated with OA of the knee for at least 6 months prior to Screening&#xD;
             and confirmation of mild to moderate OA.&#xD;
&#xD;
          3. The study knee has OA with grade 1-3 in severity based on the Kellgren-Lawrence&#xD;
             grades.&#xD;
&#xD;
          4. Females of childbearing potential to use acceptable contraceptive methods until 25&#xD;
             weeks after study drug administration.&#xD;
&#xD;
          5. Male subjects must to use acceptable contraceptive methods from dosing until 25 weeks&#xD;
             after study drug administration.&#xD;
&#xD;
          6. Willing and able to comply with study procedures and provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant abnormality at physical examination, laboratory test results or&#xD;
             positive test for hepatitis B, hepatitis C, or HIV&#xD;
&#xD;
          2. Positive urine drug screen&#xD;
&#xD;
          3. History of allergic reactions to TLC599, its components or other related drugs&#xD;
&#xD;
          4. Clinically significant and unstable illness&#xD;
&#xD;
          5. History of clinically significant autoimmune disease&#xD;
&#xD;
          6. Evidence of intra articular bleeding of the study knee&#xD;
&#xD;
          7. History of infective arthritis or suspected / concurrent infection in the study knee;&#xD;
             clinical symptoms and signs of acute infection or infection-related inflammation in&#xD;
             the non-study knee&#xD;
&#xD;
          8. Skin lesion/breakdown at the anticipated injection site or any condition that would&#xD;
             impair penetration of the study knee joint space.&#xD;
&#xD;
          9. Total white blood cell count &lt;4000/ μL or &gt;13000/ μL.&#xD;
&#xD;
         10. History of acquired or congenital immunodeficiency diseases.&#xD;
&#xD;
         11. History of treated malignancy which is disease free for ≤ 5 years&#xD;
&#xD;
         12. Stroke or myocardial infarction within 3 months&#xD;
&#xD;
         13. Subjects with a condition or in a situation which will interfere with the subject's&#xD;
             ability to comply or cooperate with the dosing and visit schedules and the protocol&#xD;
             evaluations or may not be suitable for this study&#xD;
&#xD;
         14. Clinically significant ECG abnormalities or vital sign abnormalities&#xD;
&#xD;
         15. History of significant alcohol abuse within one year or regular use of alcohol within&#xD;
             six months&#xD;
&#xD;
         16. History of significant drug abuse within one year or use of soft drugs within 3 months&#xD;
             or hard drugs within 1 year&#xD;
&#xD;
         17. Participation in a clinical research study involving the administration of an&#xD;
             investigational or marketed drug or device within 30 days, administration of a&#xD;
             biological product in the context of a clinical research study within 90 days&#xD;
&#xD;
         18. Any use of medication&#xD;
&#xD;
               1. drugs known to induce or inhibit hepatic CYP 3A4 metabolism within 30 days&#xD;
&#xD;
               2. prescription medication within 14 days&#xD;
&#xD;
               3. over-the-counter products and natural health products within 7 days&#xD;
&#xD;
               4. prescription medication known to affect platelet function within 14 days&#xD;
&#xD;
               5. a depot injection or an implant of any drug within 3 months&#xD;
&#xD;
               6. use of IA corticosteroid, hyaluronic acid, or other IA injection in the study&#xD;
                  knee within 6 months&#xD;
&#xD;
               7. any IA injection drug that could impact endogenous steroid levels within 6 months&#xD;
&#xD;
               8. systemic corticosteroids within 30 days&#xD;
&#xD;
               9. use of any chemotherapeutic or systemic immunosuppressant agents for inflammatory&#xD;
                  diseases within 6 months&#xD;
&#xD;
         19. Donation of plasma within 7 days. Donation or loss of blood of 50mL to 499 mL of blood&#xD;
             within 30 days, or more than 499 mL within 56 days&#xD;
&#xD;
         20. Female subjects who are pregnant, breast-feeding, or plan to become&#xD;
             pregnant/breast-feeding&#xD;
&#xD;
         21. History of latent or active tuberculosis or exposure to endemic areas within 8 weeks&#xD;
&#xD;
         22. Positive TB test indicating possible tuberculosis infection&#xD;
&#xD;
         23. Immunization with a live attenuated vaccine 1 month or planned during the course of&#xD;
             the study&#xD;
&#xD;
         24. History of clinically significant opportunistic infection&#xD;
&#xD;
         25. Serious local infection or systemic infection within the 3 months&#xD;
&#xD;
         26. Presence of a symptomatic viral or bacterial infection within 2 weeks&#xD;
&#xD;
         27. Subjects with current diagnosis of severe OA with grade 4 classification in the&#xD;
             non-study knee based on the Kellgren-Lawrence grades&#xD;
&#xD;
         28. Subject who had a surgery within 4 weeks or expected to have knee replacement surgery&#xD;
             scheduled during his/her study duration&#xD;
&#xD;
         29. Subjects with known history of adrenal insufficiency or with potential risk of adrenal&#xD;
             insufficiency&#xD;
&#xD;
         30. History of allergic reactions to cosyntropin&#xD;
&#xD;
         31. Patient with any lower limb amputation&#xD;
&#xD;
         32. Inadequate synovial fluid collection of the study knee joint&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Brown, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Taiwan Liposome Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ofelia Chen</last_name>
    <phone>+886 2 2655 7377</phone>
    <email>ofelia@tlcbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Panax Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Coast Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Syneos Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JBR Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Municipal Wanfang Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>116</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 16, 2018</study_first_submitted>
  <study_first_submitted_qc>November 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

